Alexander N. Shoushtari, discusses the rationale for the phase 3 CheckMate-067 trial in advanced melanoma.
Alexander N. Shoushtari, MD, an assistant attending physician at Memorial Sloan Kettering Cancer Center, discusses the rationale for the phase 3 CheckMate-067 trial in advanced melanoma.
The landmark CheckMate-067 trial randomized patients with previously untreated, advanced melanoma 1:1:1 to receive nivolumab (Opdivo) plus ipilimumab (Yervoy) followed by nivolumab, nivolumab plus ipilimumab-matched placebo, or ipilimumab plus nivolumab-matched placebo.
During the time of the study, ipilimumab monotherapy was considered the standard of care, says Shoushtari. However, nivolumab and pembrolizumab (Keytruda) have since become new standards in the space.
As such, the study evaluated whether the addition of ipilimumab to nivolumab was superior to nivolumab alone, Shoushtari concludes.